The Fentanyl Wave: When the Drug Supply Became Poison

Fentanyl killed more than 73,000 Americans in 2022 — out of 107,000 total drug overdose deaths — making overdose the leading cause of accidental death in the United States. This is not the story of a medical drug gone wrong the way OxyContin was. It is the story of a synthetic opioid manufactured illegally in Chinese and Mexican labs, introduced into the existing heroin and drug supply, and distributed through a market whose customers often did not know what they were buying.^1^ The death toll is still rising.

Part of Meth and the Opioid Crisis — ← Back to series hub

What Makes Fentanyl Lethal at Such Small Doses

Fentanyl is approximately 100 times more potent than morphine by weight. A therapeutically effective intravenous dose is measured in micrograms — millionths of a gram. A lethal dose for an opioid-naive person can be as small as two milligrams — roughly the size of a few grains of salt, invisible to the naked eye in a batch of white powder. This extreme potency, combined with the fact that illicit fentanyl is not produced under controlled conditions and its mixing into other drugs is done without precise measurement, produces a drug supply where individual doses are wildly inconsistent in potency.

Heroin dealers and other drug distributors who add fentanyl to their product — to increase potency and reduce cost — are not chemists. They are mixing a substance so potent that a variation of a few milligrams per batch can be the difference between a strong high and a fatal overdose. Fentanyl test strips can indicate whether fentanyl is present but cannot indicate concentration, leaving users unable to assess the actual risk of any given dose.^2^

How Fentanyl Entered the U.S. Drug Supply

Illicit fentanyl first appeared in the U.S. heroin supply in significant quantities around 2013. The DEA began tracking fentanyl-positive toxicology reports in overdose deaths and saw rapid increase starting in 2013 and accelerating sharply after 2016. The supply came initially primarily from China, where fentanyl analogs could be synthesized by legitimate chemical companies operating in a regulatory environment that, until Chinese government action in 2019, did not classify many fentanyl analogs as controlled substances.

After China moved to classify fentanyl and its analogs as controlled substances in May 2019 — a change that came partly in response to U.S. diplomatic pressure — production shifted substantially to Mexico. Mexican cartel chemists, primarily within the Sinaloa Cartel and CJNG, began producing fentanyl and fentanyl analogs using precursor chemicals sourced from China. By 2020, Mexico had become the dominant source of illicit fentanyl entering the United States. The smaller quantities required — fentanyl’s extreme potency means a kilogram supplies vastly more doses than a kilogram of heroin — made it easier to conceal and harder to interdict.^3^

How Counterfeit Pills Spread Fentanyl Beyond Heroin Users

Fentanyl’s deployment in the drug supply took an additional form in the late 2010s that dramatically expanded its reach: counterfeit prescription pills. Drug distributors began producing pills that visually mimicked legitimate pharmaceutical tablets — M30 oxycodone pills, Xanax bars, Adderall, Percocet — stamped with pharmaceutical markings but containing illicit fentanyl. The DEA’s 2021 “One Pill Can Kill” campaign estimated that approximately 40 percent of the counterfeit pills it analyzed contained potentially lethal doses of fentanyl.^1^

Counterfeit pills reach a demographic that never intended to use heroin: people who buy what they believe are legitimate prescription medications from informal sources, people who have developed opioid dependence on diverted prescriptions, and recreational users who believe they are buying familiar substances with known effects. The counterfeit pill problem extended fentanyl’s demographic reach dramatically and is significantly responsible for rising overdose death rates in communities — including suburban and affluent communities — that were less affected by the heroin epidemic.

The Numbers That Trace the Escalation

The CDC’s drug overdose tracking data traces a clear escalation. Opioid overdose deaths in the United States were approximately 8,000 annually in 1999, when Purdue Pharma’s OxyContin marketing was first driving the prescription opioid surge. They reached approximately 21,000 in 2010 as the prescription epidemic peaked. They continued rising as heroin replaced restricted prescriptions, reaching approximately 33,000 in 2015. The introduction of fentanyl drove a step change: 42,000 in 2016, 47,000 in 2017, and a trajectory that reached 107,000 in 2021 — the first year total drug overdose deaths exceeded 100,000.^4^

The 2021 figure represents a death toll larger than the peak annual casualties of the AIDS epidemic in the United States, larger than annual U.S. traffic fatalities, and larger than annual gun deaths.

Who Is Dying, and Where

The demographics of fentanyl deaths are more distributed across race and geography than the heroin or crack epidemics were. The National Center for Health Statistics data shows that while the absolute number of overdose deaths is highest among white Americans, rates of increase in the late 2010s and early 2020s were steepest among Black Americans — who had been somewhat buffered from the prescription opioid epidemic but were heavily affected as fentanyl entered cocaine and other drug supplies through which it was unknowingly consumed.

Native American communities have the highest overdose death rates of any racial group — 41.8 per 100,000 in 2020, compared to 30.5 per 100,000 for white Americans and 27.5 per 100,000 for Black Americans, according to CDC data.^5^ The widespread availability of naloxone (Narcan), which can reverse opioid overdoses, has saved lives but requires that someone be present to administer it, a condition that isolated users and rural communities cannot always meet.

There is no clean end to the fentanyl crisis visible on the current trajectory. Overdose death counts remain near record levels. The supply chain producing illicit fentanyl is entrenched, profitable, and distributed across two countries in ways that make interdiction marginal. Treatment capacity — medication-assisted treatment with buprenorphine and methadone, the most evidence-based interventions for opioid use disorder — remains inadequate and under-funded relative to the scale of the problem. Harm reduction infrastructure, including fentanyl test strips and supervised consumption sites, is slowly expanding but faces regulatory and political resistance in many states. The drug supply that American cities, towns, and rural communities are navigating is more dangerous than it has ever been, and the people doing the navigating are largely on their own. The Mexican super labs that produce much of this supply operate outside the reach of any domestic enforcement action, following the same adaptation logic that has defined the American drug market for fifty years.

─────────

Sources:

1. Centers for Disease Control and Prevention. Drug Overdose Deaths in the United States, 1999–2022. CDC NCHS Data Brief, 2023.
2. Drug Enforcement Administration. One Pill Can Kill: DEA Warning About Counterfeit Pills. U.S. Department of Justice, 2021.
3. Ciccarone, Daniel. “The Triple Wave Epidemic: Supply and Demand Drivers of the US Opioid Overdose Crisis.” International Journal of Drug Policy, 2019.
4. Quinones, Sam. The Least of Us: True Tales of America and Hope in the Time of Fentanyl and Meth. Bloomsbury, 2021.
5. National Center for Health Statistics. Drug Overdose Deaths in the United States by Race and Ethnicity. CDC, 2022.